Completion of Acquisition or Disposition of Assets
→
4/30/25
Exec Change
Entry into a Material Definitive Agreement
→
3/27/25
Reg FD
Regulation FD Disclosure
→
3/4/25
Agreement
Entry into a Material Definitive Agreement
→
10/24/24
Agreement
Entry into a Material Definitive Agreement
→
6/24/24
Other
Other Events
→
↓
Prospectuses & Registrations
40 shown
Filed
Form
Description
6/25/25
S-8 POS
S-8 POS
→
6/25/25
S-8 POS
S-8 POS
→
6/25/25
S-8 POS
S-8 POS
→
6/25/25
S-8 POS
S-8 POS
→
6/25/25
S-8 POS
S-8 POS
→
6/25/25
S-8 POS
S-8 POS
→
↓
Filing History(1001 filings)
TypeDateAccessionPeriodSize
SCHEDULE 13G/A
Aug 14, 2025
0000902664-25-003697
—
12.5 KB
SCHEDULE 13G/A
Aug 14, 2025
0001172661-25-003268
—
11.1 KB
15-12G
Jul 7, 2025
0001104659-25-06591515-12G
—
11.5 KB
EFFECT
Jul 1, 2025
9999999995-25-002119
—
1.7 KB
EFFECT
Jul 1, 2025
9999999995-25-002118
—
1.7 KB
EFFECT
Jul 1, 2025
9999999995-25-002112
—
1.7 KB
EFFECT
Jul 1, 2025
9999999995-25-002108
—
1.7 KB
EFFECT
Jul 1, 2025
9999999995-25-002107
—
1.7 KB
EFFECT
Jul 1, 2025
9999999995-25-002106
—
1.7 KB
EFFECT
Jul 1, 2025
9999999995-25-002105
—
1.7 KB
EFFECT
Jul 1, 2025
9999999995-25-002104
—
1.7 KB
4
Jun 27, 2025
0000950170-25-0910364
Jun 25, 2025
27.4 KB
4
Jun 27, 2025
0000950170-25-0910354
Jun 25, 2025
27.4 KB
4
Jun 27, 2025
0000950170-25-0910324
Jun 25, 2025
28.5 KB
4
Jun 27, 2025
0000950170-25-0910264
Jun 25, 2025
26.1 KB
4
Jun 27, 2025
0000950170-25-0910204
Jun 25, 2025
17.7 KB
4
Jun 27, 2025
0000950170-25-0910194
Jun 25, 2025
32.3 KB
4
Jun 27, 2025
0000950170-25-0910154
Jun 25, 2025
33.1 KB
4
Jun 27, 2025
0000950170-25-0910084
Jun 25, 2025
42.0 KB
4
Jun 27, 2025
0000950170-25-0910064
Jun 25, 2025
24.7 KB
4
Jun 27, 2025
0000950170-25-0910034
Jun 25, 2025
42.2 KB
4
Jun 27, 2025
0000950170-25-0909924
Jun 25, 2025
19.7 KB
4
Jun 27, 2025
0000950170-25-0909864
Jun 25, 2025
28.8 KB
POS AM
Jun 25, 2025
0001104659-25-062442POS AM
—
33.0 KB
POS AM
Jun 25, 2025
0001104659-25-062441POS AM
—
33.0 KB
25 filings shown
Proxies
30 shown
Filed
Form
Description
4/30/24
DEFA14A
DEFA14A
→
4/19/24
DEF 14A
DEF 14A
→
6/5/23
DEFA14A
DEFA14A
→
4/28/23
DEFA14A
DEFA14A
→
4/28/23
DEF 14A
DEF 14A
→
4/27/22
DEFA14A
DEFA14A
→
↓
Ownership
40 shown
Filed
Form
Description
6/27/25
4
4
→
6/27/25
4
4
→
6/27/25
4
4
→
6/27/25
4
4
→
6/27/25
4
4
→
6/27/25
4
4
→
↓
Other Filings
40 shown
Filed
Form
Description
8/14/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
8/14/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
7/7/25
15-12G
15-12G
→
7/1/25
EFFECT
EFFECT
→
7/1/25
EFFECT
EFFECT
→
7/1/25
EFFECT
EFFECT
→
↓
Regulus Therapeutics Inc. — SlamSEC
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases.